The Latest Breaking News from BofA

GoodRx stock soars after announcing GLP-1 partnership with Novo Nordisk. A Bank of America analyst recommends selling GDRX shares into the strength before they crash again.

On Thursday, Eli Lilly and Co. (NYSE:LLY) said it will sharply increase the list price of its weight-loss and type 2 diabetes drug Mounjaro (tirzepatide) in the United Kingdom.

Super Micro stock tanks on disappointing Q4 earnings and weaker-than-expected guidance. Here’s why SMCI shares aren’t worth buying on the post-earnings decline.

“This implies that the weak gains in payrolls in recent months might have something to do with the supply of labor.”

Ford Motor Company (NYSE:F) shares are trading higher on Thursday after the automaker posted second-quarter results that exceeded Wall Street expectations on Wednesday, driven by solid vehicle volumes and favorable pricing trends.

Pharmaceutical giants are navigating a complex landscape of fluctuating demand and regulatory hurdles, impacting their financial performance and strategic outlook. Merck Co. Inc. (NYSE:MRK) is the latest to face these challenges, as its recent earnings report reveals a mixed bag of successes and setbacks.

“Today a confluence of factors argue that the key tail risk that may not be priced in is not just a cyclical recovery, but a boom,” BofA Research analysts write.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) announced Monday it will voluntarily and temporarily pause all U.S. shipments of Elevidys, its gene therapy for Duchenne muscular dystrophy, effective July 22.

Is BofA’s Q2 revenue miss just a brief pause? Or a warning sign to rethink your position?